Onward Medical N.v. · EURONEXT:ONWD
Onward Medical — Onward Med — Q3 2025 Earnings Presentation
25 slides from Onward Medical's earnings presentation, Nov 24, 2025
Slide 1: Investor Webcast: Q3 Results & Business Update
Investor Webcast Q3 Results & Business Update November 24, 2025
Slide 2: Forward Looking Statements
Forward Looking Statements This Presentation may include statements, including the Company’s financial and operational medium-term objectives, that may be deemed to be “forward-looking statements”. These forward- looking statements may be identified by the use of forward-looking terminology, includi
Slide 3: Speaking Today
Speaking Today Dave Marver Sean Sciara Amori Fraser Chief Executive Officer Chief Commercial Officer Senior Finance Director November 2025 Webcast 3
Slide 4: Q3 2025 & YTD Highlights
Q3 2025 & YTD Highlights
Slide 5: Q3 & YTD Highlights
Since last update: Exceeded €1.5M in quarterly revenue, received CE-mark and US home use clearance for ARCEX Q3 & YTD and raised €50M in new equity capital Highlights Commercial traction Accelerated ARCEX adoption in the United States; sold 40 units in Q3 2025 and exceeded €1.5M in quarterly revenue
Slide 6: ARC-EX Commercial Traction
ARC-EX Commercial Traction
Slide 7: ARC-EX Demand Indications
As of November 24, 2025 Continued high inbound global interest ARCEX Demand Indications 5,000+ 3,300+ 430+ Global leads US leads US clinic leads collected1 collected1 collected Note: Leads defined as unsolicited inbound requests November 2025 Webcast 7 1 Lead figures include persons with SCI, family
Slide 8: ARC-EX 2025 Sales Acceleration
Sales are increasing each quarter, with ARCEX now available in over 60 clinics in the US ARCEX 2025 Sales Acceleration 2025 Sales, # of units sold 70 units sold1 30 units sold1 10 units sold Q1 Q2 Q3 Q4 Q1: Phase 0 1H: Phase I 2H: Phase II Limited US clinic launch Limited US clinic launch Broad US c
Slide 9: CE Mark & Europe Launch
First commercial sale in Europe expected in Q4 2025; initial focus on DACH, Netherlands, CE Mark & and UK Europe Launch First commercial sale in Europe expected in Q4 2025 Initial focus: Germany Switzerland Austria Netherlands UK Planning hybrid go-to-market approach in Europe: Direct sales and dist
Slide 10: US Home Use Clearance
Received FDA 510(k) clearance expanding ARCEX indication for home use in the US, US Home Use enlarging market opportunity Clearance US FDA 510(k) clearance now allows use of the ARCEX System both in clinics and homes Enables people living with SCI to benefit from ARCEX in the comfort and convenience
Slide 11: ARC-EX US Home Use Logistics
Clinics will partner with ONWARD to ARCEX US Home Use provide set-up and support Logistics Ordering Billing Delivery Set-up Support Prescriptions are Payor is billed Device is shipped to Device is set-up and 1) Everyday support provided by clinics validated by an through an patient’s home programmed
Slide 12: Other Achievements
Other Achievements
Slide 13: Capital Raise
Raised over €50M in equity capital, extending cash runway into Q1 2027 Capital Raise o Over €50M in equity capital raised, supported by demand from high-quality, long-only and sector specialist investors o Anchor investors were Ottobock, a global player in prosthetics, orthotics and exoskeleton tech
Slide 14: UL Mark
Received UL Mark Certification, UL Mark reinforcing engineering and process integrity underlying ARCEX System o Certifies that ONWARD meets rigorous standards required by UL Solutions across: - Design documentation - Certifications - Component traceability - Safety test reports o Opens doors to US c
Slide 15: Scientific Publications
Concurrent Nature and Nature Medicine publications detailing blood pressure feasibility Scientific study results and mechanism; publication on LIFT Publications Home study results An implantable system to A neuronal architecture Home-Based Noninvasive Spinal restore hemodynamic underlying autonomic
Slide 16: Home Use Results ARC-EX Therapy
LIFT Home trial results support the safety, usability, and therapeutic benefits of at-home ARCEX Home Use Results Therapy as a continuation of in-clinic treatment* (n=17, 5 trial sites in the US) ARCEX Therapy 96% Attempted home therapy sessions completed Compliance with the prescribed therapy was h
Slide 17: EMPOWER BP Site Activation
The first site for EMPOWER BP has been activated EMPOWER BP Site Activation Following IDE approval for the EMPOWER BP pivotal study in August 2025, the first research site has been activated November 2025 Webcast 17
Slide 18: Corporate Update
Strengthened leadership and ability to scale with the appointment of new Corporate Update senior executives Sean Sciara Ali Kiboro Shari O’Quinn Chief Commercial Officer Chief Financial Officer Chief Clinical, Regulatory and Quality Officer Promoted from VP Marketing at CFO at AliveDx and former VP
Slide 19: Q3 2025 Financial Results
Q3 2025 Financial Results
Slide 20: Q3 2025 Cash Update
Strengthened balance sheet with proceeds from October 2025 capital Q3 2025 raise; continued disciplined capital Cash Update management Burn Ending Current Cash Revenue €8.0M used Balance Q3 Balance €1.7M in Q3 20251 during Q3 2025 €32.9M net cash2 €77.7M net cash2 as of 30 Sep as of 31 Oct 2025 2025
Slide 21: Outlook
Outlook
Slide 22: Milestones and News Flow
Major milestones completed and important catalysts expected in the coming months Milestones and ARCEX ARCIM ARCBCI News Flow ARCEX ARCEX ARCEX ARCEX ARCEX FDA authorization (US) First commercial sale CE mark (EU) FDA Home use First commercial sale Hand sensation & strength (US) Hand sensation & stre
Slide 23: Q&A
Q&A
Slide 24: Thank you!
Thank you! 24
Slide 25: ONWARD Medical